Development of novel devices for assessing drugs promoting neuronal regeneration

Ananda Devices是一家总部位于蒙特利尔的中小企业，致力于开发和制造微流体/器官芯片设备，以提高细胞分析的可重复性和效率。Ananda**Devices的专利neuromfd提供了一种更有效的模型来体外测试针对神经退行性疾病的药物。当前一代的神经- mfd每次实验只能测试一种药物，而大型实验室和生物制药行业需要测试数千种药物。阿南达设备旨在开发一种新型设备**(即：ht - neuromfd)，可用于自动化药物测试过程。**与David Juncker博士合作，将neural - mfd的当前优势扩展到ht - neural - mfd，**Ananda Devices将受益于科学，工程和技术专业知识和工具，以开发**创新产品，以响应市场需求，加速神经系统疾病的药物发现。**本项目详述的活动将以多种方式使加拿大受益：**-技术：拟议的创新研究将培养生物工程、**神经科学和微流体装置领域的人才，以确保加拿大在这些前沿领域保持领先地位。**-出口：阿南达设备80%以上的收入来自出口销售，从而使加拿大处于这些创新的前沿，有可能使所有加拿大人在经济上受益，并促进**加拿大知识产权的产出。**健康：这项研究最终将有助于开发治疗神经退行性疾病的新药，如帕金森氏症、阿尔茨海默氏症、多发性硬化症和ALS。

Ananda Devices is a Montreal based SME dedicated to the development and manufacturing of**microfluidic/organ-on-a-chip devices to increase reproducibility and efficiency of cellular assays. Ananda**Devices' proprietary Neuro-MFD offers a more efficient model to test drugs targeting neurodegenerative**diseases in vitro.**Current generation of Neuro-MFD can only test one drug per experiment and larger labs and the**biopharmaceutical industry need to test thousands of drugs. Ananda Devices aims to develop a novel device**(i.e., HT-Neuro-MFD) that can be adapted to automate the drug testing process.**Partnering with Dr. David Juncker to scale the current advantages of the Neuro-MFD to an HT-Neuro-MFD,**Ananda Devices will benefit from scientific, engineering and technical expertise and tools to develop an**innovative product to respond to the market's demand to accelerate drug discovery in neurological diseases.**The activities detailed in this Project will benefit Canada in a variety of ways:**-Technology: The proposed innovative research will train personnel in the areas of bioengineering,**neuroscience, and microfluidic devices to ensure that Canada remains a leader in these cutting-edge fields.**-Export: Over 80% of Ananda Devices's revenue results from export sales, thereby putting Canada at the**forefront of these innovations has the potential to benefit all Canadians economically and advance the output of**Canadian intellectual property.**-Health: The research will ultimately contribute to the development of new drugs that treat neurodegenerative**diseases, such as Parkinson, Alzheimer's, Multiple Sclerosis and ALS.